Therefore, ANF-mediated inhibition of PKCί represents a novel therapeutic strategy for NSCLC patients with high ELF3 levels regardless of mutations in EGFR or other main oncogenes such as K-Ras. This evidence concerns the gene ELF3 and non-small cell lung carcinoma.